Estudo randomizado | Metformina, ivermectina e fluvoxamina não são benéficas para pacientes ambulatoriais obesos com Covid-19.

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 – New England Journal of Medicine

Editorial: Time to Stop Using Ineffective Covid-19 Drugs – New England Journal of Medicine

Comentário no Twitter

In this trial involving overweight or obese outpatients with Covid-19, investigators found that none of three repurposed drugs (metformin, ivermectin, and fluvoxamine) reduced the risk of serious disease. https://t.co/8sd6R7CDK6 pic.twitter.com/bPZ6zeuZSA

— NEJM (@NEJM) August 17, 2022